Increased Expression of RUNX1 in Liver Correlates with NASH Activity Score in Patients with Non-Alcoholic Steatohepatitis (NASH)

Increased Expression of RUNX1 in Liver Correlates with NASH Activity Score in Patients with Non-Alcoholic Steatohepatitis (NASH)

Given the important role of angiogenesis in liver pathology, the current study investigated the role of Runt-related transcription factor 1 (RUNX1), a regulator of developmental angiogenesis, in the pathogenesis of non-alcoholic steatohepatitis (NASH). Quantitative RT-PCRs and a transcription factor...

Descrición completa

Detalles Bibliográficos
Main Authors:	Savneet Kaur, Preety Rawal, Hamda Siddiqui, Sumati Rohilla, Shvetank Sharma, Dinesh M Tripathi, Sukriti Baweja, Mohsin Hassan, Sebastian Vlaic, Reinhard Guthke, Maria Thomas, Rania Dayoub, Chaggan Bihari, Shiv K. Sarin, Thomas S. Weiss
Formato:	Artigo
Idioma:	English
Publicado:	MDPI AG 2019-10-01
Series:	Cells
Subjects:	angiogenesis inflammation non-alcoholic fatty liver disease fatty liver steatosis runx1
Acceso en liña:	https://www.mdpi.com/2073-4409/8/10/1277

Títulos similares

Free fatty acid-based low-impedance liver image: a characteristic appearance in nonalcoholic steatohepatitis (NASH)
por: Hitoshi Maruyama, et al.
Publicado: (2020-01-01)

The role of the microbiome in NAFLD and NASH
por: Aleksandra A Kolodziejczyk, et al.
Publicado: (2018-12-01)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
por: Elliot B. Tapper, et al.
Publicado: (2023-04-01)

Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database
por: Karishma Shelley, et al.
Publicado: (2023-05-01)

Genetic deletion or pharmacologic inhibition of the Nlrp3 inflammasome did not ameliorate experimental NASH
por: George N. Ioannou, et al.
Publicado: (2023-02-01)

acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study
por: Xi-Xi Wu, et al.
Publicado: (2021-11-01)

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs
por: Stephen Caldwell
Publicado: (2017-06-01)

Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH
por: Jonathan G. Stine, et al.
Publicado: (2020-06-01)

Bofutsushosan (Fangfengtongshengsan) improves early stages of NASH via the gut–liver axis in diabetes-induced NASH model mice
por: Mitsue Nishiyama, et al.
Publicado: (2024-06-01)

Noninvasive Diagnosis of NAFLD and NASH
por: Valeria Annarita Piazzolla, et al.
Publicado: (2020-04-01)

The role of oxidized lipid species in insulin resistance and NASH in children
por: Nicola Santoro, et al.
Publicado: (2022-10-01)

NASH: A glance at the landscape of pharmacological treatment
por: Lucia Brodosi, et al.
Publicado: (2016-09-01)

The Influence of Different Fat Sources on Steatohepatitis and Fibrosis Development in the Western Diet Mouse Model of Non-alcoholic Steatohepatitis (NASH)
por: Hannah K. Drescher, et al.
Publicado: (2019-06-01)

Corrigendum: The role of oxidized lipid species in insulin resistance and NASH in children
por: Nicola Santoro, et al.
Publicado: (2024-12-01)

Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH[S]
por: George N. Ioannou, et al.
Publicado: (2017-06-01)

DIAGNOSTIC ACCURACY OF THE NON-INVASIVE MARKERS NFLS, NI-NASH-DS, AND FIB-4 FOR ASSESSMENT OF DIFFERENT ASPECTS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN INDIVIDUALS WITH OBESITY: CROSS-SECTIONAL STUDY
por: Gustavo Macedo HADDAD, et al.
Publicado: (2024-06-01)

NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
Publicado: (2012-04-01)

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
por: Ryan D. Welch, et al.
Publicado: (2022-03-01)

Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targetsKey points
por: Cristiana Bianco, et al.
Publicado: (2021-06-01)

Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH
por: Ankoor H. Patel, et al.
Publicado: (2024-07-01)

Preventing NASH with Empagliflozin and Linagliptin: A Diabetic Drug Combination
por: Asma Abdul Razzak, et al.
Publicado: (2023-10-01)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
por: Martina Colognesi, et al.
Publicado: (2020-07-01)

Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
por: Cristina Piras, et al.
Publicado: (2021-10-01)

Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis[S]
por: Petra Hirsova, et al.
Publicado: (2016-10-01)

TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism
por: Christopher R. Shepard
Publicado: (2021-01-01)

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH
por: Theresa J. Hydes, et al.
Publicado: (2020-10-01)

Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH)
por: Helena Cortez-Pinto, et al.
Publicado: (2016-05-01)

Histological findings and NAFLD/NASH Status in liver biopsies of patients subjected to bariatric surgery
por: Marielle Malucelli, et al.
Publicado: (2023-11-01)

Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs
por: Eleftheria Galatou, et al.
Publicado: (2022-05-01)

Human umbilical cord mesenchymal stem cells attenuate diet-induced obesity and NASH-related fibrosis in mice
por: Jiali Hu, et al.
Publicado: (2024-02-01)

Deciphering the role of aberrant DNA methylation in NAFLD and NASH
por: Meenakshi Vachher, et al.
Publicado: (2022-10-01)

The Role of RECK in Hepatobiliary Neoplasia Reveals Its Therapeutic Potential in NASH
por: Ryan J. Dashek, et al.
Publicado: (2021-10-01)

Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model SystemsSummary
por: Trenton T. Ross, et al.
Publicado: (2020-01-01)

Vitamin E does not prevent Western diet-induced NASH progression and increases metabolic flux dysregulation in mice
por: Clinton M. Hasenour, et al.
Publicado: (2020-05-01)

Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis
por: D.N. Amarapurkar, et al.
Publicado: (2006-01-01)

The Patient Perspectives on Future Therapeutic Options in NASH and Patient Needs
por: Nigel Cook, et al.
Publicado: (2019-04-01)

Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition
por: Genta Kakiyama, et al.
Publicado: (2020-12-01)

Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl<sub>4</sub>-Induced NASH Mice and the Effect of Obeticholic Acid
por: Nanlin Zhu, et al.
Publicado: (2021-06-01)

A significant and persistent rise in the global burden of adolescent NAFLD and NASH estimated by BMI
por: Xiao-Yun Lin, et al.
Publicado: (2024-10-01)

Vitamin C Deficiency May Delay Diet-Induced NASH Regression in the Guinea Pig
por: Josephine Skat-Rørdam, et al.
Publicado: (2021-12-01)